Presentation Number: Presentation Title – Presenting Author
Additional Exploratory Biomarkers Under
Investigation for I-O Therapies
1−12
Biomarker
investigations
TILs/
immunoscore
(eg, CD4 and CD8
T cells)
Gene expression
signatures
Other tumor immune
marker expression
(eg, CTLA-4, PD-L2)
Mutational load/burden,
neo-antigens
TCR sequencing
Other known oncogenic
driver mutations
(eg,
EGFR
,
KRAS
,
BRAF
)
Tumor
biomarkers
Immune monitoring: absolute
lymphocyte count, circulating
T-cell subsets
Gene expression
profiling:
peripheral blood
TCR
sequencing
Serum chemokines/cytokines:
interferons, interferon inducible
factors, serum soluble factors
sPD-L1
Circulating
miRNAs
Antitumor
antibodies
SNPs
(germline)
Peripheral
biomarkers
1. Sosman JA et al. Poster presentation at ASCO 2013. TPS3114. 2. Choueiri TK et al. Oral presentation at ASCO 2015. 4500. 3. Clinical Protocol CA209009. 4. Lawrence MS et al.
Nature
. 2013;499(7457):214-
218.5. Antonia SJ et al. Poster presentation at WCLC 2013. P2.11-035. 6. Weber JS et al.
Lancet Oncol
. 2015;16(4):375-384. 7. Brown SD et al.
Genome Res
. 2014;24(5):743-750. 8. Postow MA et al.
J Transl
Med
. 2014;12(suppl 1):O8. 9. Komatsu N et al.
Cancer
. 2012;118(12):3208-3221. 10. Wang Z et al.
Med Hypotheses
. 2013;81(1):41-43. 11. Luborsky J et al.
Am J Reprod Immunol
. 2005;54(2):55-62. 12. Schneider
BP et al.
Lancet Oncol
. 2012;13(10):e427-e436.
41
